^
CANCER:

Gastrointestinal Cancer

5d
ALK (Anaplastic lymphoma kinase)
|
ALK fusion • ALK mutation • ALK G1202R • ALK V1180L
|
Guardant360® CDx
|
5-fluorouracil • Alecensa (alectinib) • Lorbrena (lorlatinib) • leucovorin calcium
7d
Clinical • Next-generation sequencing
|
ALK (Anaplastic lymphoma kinase)
|
ALK fusion • ALK mutation
|
5-fluorouracil • Alecensa (alectinib) • oxaliplatin • leucovorin calcium • Emla-cream
12d
CAR T-Cell Therapy
|
CLDN18 (Claudin 18) • CLDN8 (Claudin 8)
12d
HER-2 (Human epidermal growth factor receptor 2)
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
13d
Review
|
TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset)
|
TMB-H
|
Keytruda (pembrolizumab) • Lynparza (olaparib)
18d
TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • NTRK (Neurotrophic receptor tyrosine kinase)
|
TMB-H • NTRK positive • NTRK fusion
26d
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12C • KRAS G12
27d
Clinical
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
|
RAS wild-type • PIK3CA E542K • PIK3CA E542
|
5-fluorouracil • everolimus • Vectibix (panitumumab) • Piqray (alpelisib) • leucovorin calcium • aspirin
1m
VEGFA (Vascular endothelial growth factor A)
1m
Clinical
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • RAD51C (RAD51 paralog C)
|
HRD
1m
BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • BRAF mutation
1m
KRAS (KRAS proto-oncogene GTPase) • ITGA6 (Integrin, alpha 6)
|
KRAS mutation
2ms
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • NTRK (Neurotrophic receptor tyrosine kinase)
|
KRAS G12C • KRAS G12
2ms
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12
2ms
Clinical • NCCN guideline
|
PALB2 (Partner and localizer of BRCA2) • BRCA (Breast cancer early onset)
|
PALB2 mutation • BRCA mutation
|
Rubraca (rucaparib)
2ms
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
Herceptin (trastuzumab) • Perjeta (pertuzumab)
2ms
BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • NRG1 (Neuregulin 1) • NTRK (Neurotrophic receptor tyrosine kinase)
|
NRG1 fusion • NRG1 rearrangement
2ms
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12C • KRAS G12
2ms
BRAF (B-raf proto-oncogene)
|
BRAF mutation
2ms
PALB2 (Partner and localizer of BRCA2)
2ms
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12C • KRAS G12
2ms
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • FGFR2 (Fibroblast growth factor receptor 2) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NRG1 (Neuregulin 1)
|
KRAS wild-type • RAS wild-type
2ms
STK11 (Serine/threonine kinase 11) • PALB2 (Partner and localizer of BRCA2) • MSH6 (MutS homolog 6) • MLH1 (MutL homolog 1) • BRCA (Breast cancer early onset)
2ms
Mismatch repair
|
MSH6 (MutS homolog 6) • MLH1 (MutL homolog 1) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2) • EPCAM (Epithelial cell adhesion molecule)
|
MSH2 mutation • PMS2 mutation
2ms
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation
|
Tibsovo (ivosidenib)
2ms
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
3ms
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
|
adagrasib (MRTX849)
3ms
Liquid biopsy • Circulating tumor DNA
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
KRAS mutation • HER-2 amplification
3ms
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
|
HER-2 amplification • PD-L1 amplification
|
Keytruda (pembrolizumab)
3ms
Clinical
|
MTAP (Methylthioadenosine Phosphorylase) • PRMT5 (Protein Arginine Methyltransferase 5)
|
MTAP deletion
|
MRTX1719
3ms
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
|
adagrasib (MRTX849)
3ms
Clinical • Liquid biopsy • Minimal residual disease
|
Guardant360® CDx
3ms
Clinical • Combination therapy
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
|
Erbitux (cetuximab) • adagrasib (MRTX849)